GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 2 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $810,000 | +30.9% | 11,900 | +21.3% | 0.00% | +33.3% |
| Q2 2020 | $619,000 | +66.4% | 9,812 | +34.4% | 0.00% | +50.0% |
| Q1 2020 | $372,000 | -41.4% | 7,300 | -8.8% | 0.00% | -33.3% |
| Q4 2019 | $635,000 | +9.1% | 8,000 | -33.3% | 0.00% | +200.0% |
| Q3 2019 | $582,000 | +78.5% | 12,000 | +93.5% | 0.00% | 0.0% |
| Q2 2019 | $326,000 | +58.3% | 6,200 | +59.0% | 0.00% | 0.0% |
| Q1 2019 | $206,000 | +216.9% | 3,900 | +143.8% | 0.00% | – |
| Q4 2018 | $65,000 | +400.0% | 1,600 | +220.0% | 0.00% | – |
| Q2 2017 | $13,000 | -27.8% | 500 | 0.0% | 0.00% | – |
| Q1 2017 | $18,000 | +157.1% | 500 | 0.0% | 0.00% | – |
| Q4 2016 | $7,000 | -36.4% | 500 | 0.0% | 0.00% | – |
| Q3 2016 | $11,000 | -85.7% | 500 | -89.4% | 0.00% | – |
| Q2 2016 | $77,000 | +126.5% | 4,700 | +113.6% | 0.00% | – |
| Q1 2016 | $34,000 | -52.1% | 2,200 | 0.0% | 0.00% | – |
| Q4 2015 | $71,000 | -22.8% | 2,200 | 0.0% | 0.00% | – |
| Q3 2015 | $92,000 | – | 2,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |